Sutou Shizuyo, Kunishi Miho, Kudo Toshiyuki, Wongsrikeao Pimprapar, Miyagishi Makoto, Otoi Takeshige
School of Pharmacy, Shujitsu University, Nishigawara, Okayama, Japan.
BMC Biotechnol. 2007 Jul 26;7:44. doi: 10.1186/1472-6750-7-44.
Since prion gene-knockout mice do not contract prion diseases and animals in which production of prion protein (PrP) is reduced by half are resistant to the disease, we hypothesized that bovine animals with reduced PrP would be tolerant to BSE. Hence, attempts were made to produce bovine PRNP (bPRNP) that could be knocked down by RNA interference (RNAi) technology. Before an in vivo study, optimal conditions for knocking down bPRNP were determined in cultured mammalian cell systems. Factors examined included siRNA (short interfering RNA) expression plasmid vectors, target sites of PRNP, and lengths of siRNAs.
Four siRNA expression plasmid vectors were used: three harboring different cloning sites were driven by the human U6 promoter (hU6), and one by the human tRNAVal promoter. Six target sites of bovine PRNP were designed using an algorithm. From 1 (22 mer) to 9 (19, 20, 21, 22, 23, 24, 25, 27, and 29 mer) siRNA expression vectors were constructed for each target site. As targets of siRNA, the entire bPRNP coding sequence was connected to the reporter gene of the fluorescent EGFP, or of firefly luciferase or Renilla luciferase. Target plasmid DNA was co-transfected with siRNA expression vector DNA into HeLaS3 cells, and fluorescence or luminescence was measured. The activities of siRNAs varied widely depending on the target sites, length of the siRNAs, and vectors used. Longer siRNAs were less effective, and 19 mer or 21 mer was generally optimal. Although 21 mer GGGGAGAACTTCACCGAAACT expressed by a hU6-driven plasmid with a Bsp MI cloning site was best under the present experimental conditions, the corresponding tRNA promoter-driven plasmid was almost equally useful. The effectiveness of this siRNA was confirmed by immunostaining and Western blotting.
Four siRNA expression plasmid vectors, six target sites of bPRNP, and various lengths of siRNAs from 19 mer to 29 mer were examined to establish optimal conditions for knocking down of bPRNP in vitro. The most effective siRNA so far tested was 21 mer GGGGAGAACTTCACCGAAACT driven either by a hU6 or tRNA promoter, a finding that provides a basis for further studies in vivo.
由于朊病毒基因敲除小鼠不会感染朊病毒疾病,并且朊病毒蛋白(PrP)产量减半的动物对该疾病具有抗性,我们推测PrP含量降低的牛对牛海绵状脑病具有耐受性。因此,人们尝试利用RNA干扰(RNAi)技术生产可被敲低的牛PRNP(bPRNP)。在进行体内研究之前,先在培养的哺乳动物细胞系统中确定敲低bPRNP的最佳条件。研究的因素包括小干扰RNA(siRNA)表达质粒载体、PRNP的靶位点以及siRNA的长度。
使用了四种siRNA表达质粒载体:三种带有不同克隆位点的载体由人U6启动子(hU6)驱动,一种由人tRNAVal启动子驱动。使用一种算法设计了六个牛PRNP的靶位点。针对每个靶位点构建了1(22 mer)至9(19、20、21、22、23、24、25、27和29 mer)个siRNA表达载体。作为siRNA的靶标,整个bPRNP编码序列与荧光增强型绿色荧光蛋白(EGFP)、萤火虫荧光素酶或海肾荧光素酶的报告基因相连。将靶质粒DNA与siRNA表达载体DNA共转染到HeLaS3细胞中,并测量荧光或发光。siRNA的活性因靶位点、siRNA长度和所用载体的不同而有很大差异。较长的siRNA效果较差,19 mer或21 mer通常是最佳的。尽管在当前实验条件下,由带有Bsp MI克隆位点的hU6驱动质粒表达的21 mer GGGGAGAACTTCACCGAAACT效果最佳,但相应的tRNA启动子驱动质粒几乎同样有效。通过免疫染色和蛋白质印迹证实了这种siRNA的有效性。
研究了四种siRNA表达质粒载体、六个bPRNP靶位点以及19 mer至29 mer的各种长度的siRNA,以确定体外敲低bPRNP的最佳条件。迄今为止测试的最有效的siRNA是由hU6或tRNA启动子驱动的21 mer GGGGAGAACTTCACCGAAACT,这一发现为进一步的体内研究提供了基础。